Patrick O'Brien, General Counsel at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 45,734 shares at $61.88 ($2.8M) on 2022-01-05, disclosed to the SEC on 2022-01-07.
Seasonal sale ($2.8M) by General Counsel — this insider has traded ARWR in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 800 | $0 | 0.0% |
| 2 | $60.49 | 12,434 | $752K | 27.3% |
| 3 | $60.49 | 12,434 | $752K | 27.3% |
| 4 | $61.88 | 10,350 | $640K | 23.2% |
| 5 | $62.49 | 5,000 | $312K | 11.3% |
| 6 | $63.75 | 4,400 |
| $281K |
| 10.2% |
| 7 | $64.35 | 316 | $20K | 0.7% |
| Total | $60.31 avg | 45,734 | $2.8M | 100% |
| Filing → |
| GLRE | SELL | 2025-05-14 | $267K | — | Filing → |
| ARWR | SELL | 2025-01-07 | $1.3M | — | Filing → |
| ARWR | SELL | 2024-01-05 | $1.9M | — | Filing → |